Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Operating Expenses: $33.7 million for Q3 2025, $119.8 million for the nine months ended September 30, 2025. R&D Expenses: $23.3 million for Q3 2025, $87.7 million for the nine months ended September 30, 2025. G&A Expenses: $10.4 million for Q3 2025, $32.1 million for the nine months ended September 30, 2025. Net Loss: $13.5 million or $0.49 per diluted share for Q3 2025. Cash Position: $237.3 million as of September 30, 2025. Warning! GuruFocus has detected 4 Warning Signs with ARCT. Is ARCT fairly valued? Test your thesis with our free DCF calculator. Release Date: November 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Arcturus Therapeutics Holdings Inc ( NASDAQ:ARCT ) reported positive interim Phase 2 data for its ARCT-032 program, showing reductions in mucus burden in cystic fibrosis patients. The ARCT-810 program for ornithine transcarbamylase deficiency has shown positive interim
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Piper Sandler from $140.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- ARCT's page on the SEC website